Symbols

PSNL

Personalis·NASDAQ

--(--)

PSNL fundamentals

PSNL Q4 2025 Earnings

Personalis (PSNL) released its earnings on Feb 26, 2026: revenue was 17.34M (YoY +3.24%), beat estimates; EPS was -0.26 (YoY -13.04%), beat estimates.

Revenue / YoY

17.34M

+3.24%

EPS / YoY

-0.26

-13.04%

Report date

Feb 26, 2026

PSNL Earnings Call Summary for Q4,2025

Clinical Growth Surge: 2025 Clinical tests up 329% YoY, 2026 targets 43,000-45,000 tests (170% growth).
Medicare Wins Validate: Breast and lung cancer coverage secured, IO coverage pending.
Biopharma Strength: MRD revenue +240% YoY to $49M, pharma partnerships driving innovation.
Gross Margin Challenge: 2026 gross margin 15%-20% due to unreimbursed volume, cash burn $105M.
Real-Time Innovation: Variant tracker module gains early physician traction, enhancing MRD utility.

Earnings

EPS

Revenue

Revenue & Expenses

PSNL has released its 2025 Q4 earnings report, with revenue of 17.34M, reflecting a YoY change of 3.24%, and net profit of -23.81M, showing a YoY change of -44.97%. The Sankey diagram below clearly presents PSNL's revenue sources and cost distribution.

Key Indicators

Personalis (PSNL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Personalis (PSNL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Personalis (PSNL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Personalis (PSNL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown